Updated recommendations for use of Pfizer–BioNTech, Moderna and Janssen vaccines

June 15, 2021

68

June 15, 2021: The interim recommendations for use of Pfizer-BioNTech BNT162b2, Moderna mRNA–1273 and Janssen Ad26.COV2.S vaccines have been updated to reflect latest evidence.

For further information, see below:Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

- Advertisement -

Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine

Updated recommendations for use of Pfizer–BioNTech, Moderna and Janssen vaccines

LEAVE A REPLY Cancel reply

Most Popular

What is Decentralized clinical trials?:Benefits and challenges of implementing DCT

FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US

FDA Clears First Over-the-Counter Continuous Glucose Monitor

FDA, Industry Actions End Sales of PFAS Used in US Food Packaging

EDITOR PICKS

Job Interview Questions for Clinical Data Management 2024

CRASH COURSE ON CLINICAL DATA MANAGEMENT

Interview Questions on Institutional Review Board(IRB)

POPULAR POSTS

How to Find Paid Clinical Trials Near You

What Is CDISC and What Are CDISC Data Standards?

What is Dechallenge, Rechallenge and Prechallenge in Clinical trials?

POPULAR CATEGORY

ABOUT US

FOLLOW US

Updated recommendations for use of Pfizer–BioNTech, Moderna and Janssen vaccines

RELATED ARTICLES

LEAVE A REPLY Cancel reply

Most Popular

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

FOLLOW US